Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy desig...
Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah's CAR-T cell therapy.AMC anno...
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or r...
Sept 2022: The treatment of various tumours has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. In order to target and combat specific forms of leukaemia and lymphoma,...
Sept 2022: According to a study published in the Journal of Clinical Investigation, an engineer at the University of Houston (UH) may have discovered a mechanism to identify which lymphoma patients a...
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell...
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a ...
June 2022: According to the findings of a study that was just recently published by Stanford Medicine in mice, a cancer treatment that makes use of a patient's own genetically modified immune cells i...
April 2022: According to preliminary data from a phase I/II clinical trial that was presented during the AACR Annual Meeting 2022, which was held from April 8-13, a new chimeric antigen receptor (CAR...
Nov 2021: The first clinical trial of South Korea's homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently...